SiteOne Therapeutics develops drugs that target sodium channels, the “wiring” in the body that transmits pain signals. Because SiteOne’s targets are located in the peripheral nervous system, they should not pose the same addiction risks as opioids, which hit receptors in the central nervous system.
The post Startup SiteOne Secures $100M to Forge Ahead With Novel Non-Opioid Pain Meds appeared first on MedCity News.
